Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Matthew Parke's research focuses on the characterization of rare sarcomas, specifically investigating novel tumor entities defined by gene fusions. His work includes the identification and description of POU2AF3-rearranged sarcomas, a newly defined tumor type associated with fusions involving EWSR1 or FUS. Parke also studies complex infectious disease presentations in immunocompromised individuals, including concomitant disseminated histoplasmosis and atypical mycobacterial infections in patients with HIV. His research output includes two publications and has garnered 13 citations, with an h-index of 1. He collaborates with Soumya Pandey at the University of Arkansas for Medical Sciences, with whom he has co-authored one publication.
Metrics
- h-index: 1
- Publications: 2
- Citations: 13
Selected Publications
-
Concomitant and disseminated histoplasma and atypical mycobacterial infection complicating <scp>HIV</scp> infection (2023)
-
<scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp> (2023)
Collaboration Network
Top Collaborators
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
- <scp>POU2AF3</scp>‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>
Similar Researchers
Based on overlapping research topics